• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.

作者信息

Kereiakes D J, Broderick T M, Abbottsmith C, Shimshak T M

机构信息

Medical Director, Lindner Center for Research and Education, Cincinnati, OH 45219, USA.

出版信息

J Invasive Cardiol. 2000 Feb;12(2):95-8.

PMID:10731271
Abstract
摘要

相似文献

1
Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.阿昔单抗用于经皮冠状动脉介入治疗后的出血风险和血管并发症：对一个老问题的新审视
J Invasive Cardiol. 2000 Feb;12(2):95-8.
2
Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.经皮冠状动脉介入治疗联合使用阿昔单抗后的出血和血管并发症。
Mayo Clin Proc. 2001 Sep;76(9):890-6. doi: 10.4065/76.9.890.
3
Vascular complications after percutaneous coronary interventions using abciximab (Reopro ): prospective evaluation with Doppler color flow imaging.
J Invasive Cardiol. 2000 Feb;12(2):86-94.
4
Readministration of abciximab in percutaneous coronary intervention.阿昔单抗在经皮冠状动脉介入治疗中的再次给药。
J Invasive Cardiol. 1999 Apr;11(4):251-8.
5
Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
J Cardiovasc Pharmacol Ther. 2008 Jun;13(2):89-93. doi: 10.1177/1074248408316485. Epub 2008 Apr 15.
6
Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions.阿昔单抗在接受经皮冠状动脉介入治疗的慢性肾功能不全患者中的安全性。
Am Heart J. 2003 Aug;146(2):345-50. doi: 10.1016/S0002-8703(03)00231-X.
7
Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?英国国家临床优化研究所的指南是否适用于教学医院环境中阿昔单抗在经皮冠状动脉介入治疗中的“实际应用”？
Int J Clin Pract. 2006 Apr;60(4):498-9. doi: 10.1111/j.1368-5031.2006.0827c.x.
8
Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.封堵装置时代接受血小板糖蛋白IIb/IIIa抑制剂治疗患者的穿刺部位结局
Catheter Cardiovasc Interv. 2003 Jan;58(1):1-5. doi: 10.1002/ccd.10384.
9
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.两种血小板糖蛋白IIb/IIIa抑制剂——替罗非班和阿昔单抗在经皮冠状动脉血运重建术中预防缺血事件的比较。
N Engl J Med. 2001 Jun 21;344(25):1888-94. doi: 10.1056/NEJM200106213442502.
10
Care of the patient receiving ReoPro following angioplasty.
J Invasive Cardiol. 1994;6 Suppl A:38A-42A; discussion 54A-56A.